8-K ·Filed Sep 28, 2026
8-K context-dependent: Items 7.01
Actionable Insight • Neutral
No efficacy or safety data yet — the catalyst is the first-half 2027 data readout. Monitor for enrollment updates and any preclinical or biomarker disclosures in the interim.
Latest settled — T+20d
KROS ▲ +0.44% at T+20d
NEUTRAL call +0.44% · α vs SPY +0.47% · entry $11.28 → $11.33
T+1d
-0.80%
call -0.80% · α -0.61%
$11.19
settled 28d ago
T+5d
+2.13%
call +2.13% · α +0.92%
$11.52
settled 22d ago
T+20d
+0.44%
call +0.44% · α +0.47%
$11.33
settled 23h ago
T+60d
Pending
in 8w
Price Chart
Loading chart...
Executive Summary
Keros Therapeutics announced the first patient was dosed in its Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy (DMD). Initial data is expected in the first half of 2027. This is an early-stage operational milestone with no financial data or efficacy results disclosed.
Key Facts
- First patient dosed in Phase 2 open-label, multi-cohort basket trial (NCT07704099) of rinvatercept in DMD.
- Primary objective: safety and tolerability in late-ambulatory and early non-ambulatory DMD patients.
- Initial data expected in the first half of 2027.
- Rinvatercept is also being developed for ALS.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech.
Risk Factors
- Clinical trial enrollment delays or safety issues could push back data timeline.
- Rinvatercept is early-stage; no approved products or revenue stream to buffer setbacks.
- Competing DMD therapies may set a high efficacy bar.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000056 |
| Exhibit: exhibit99192826pr.htm | 0001664710-26-000056 |
| Document: 0001664710-26-000056-index-headers.html | 0001664710-26-000056 |
| Document: 0001664710-26-000056-index.html | 0001664710-26-000056 |
| Document: 0001664710-26-000056.txt | 0001664710-26-000056 |
21 reports for KROS
100% Hit rate @ T+1 Went positive at some point 5 of 5 best @ T+60▲ +12.51%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $11.19 $11.40 | ▲ +1.88% | ▲ +2.08% | $11.33 (+1.25%) |
Sep 28, 2026 28d ago | 8-K | $11.28 $11.19 | ▼ −0.80% | ▼ −0.61% | $11.33 (+0.44%) |
Sep 28, 2026 28d ago | Press Release | $11.28 $11.19 | ▼ −0.80% | ▼ −0.61% | $11.33 (+0.44%) |
Sep 17, 2026 5w ago | EFFECT | $11.36 $11.19 | ▼ −1.50% | ▼ −1.38% | $11.33 (−0.26%) |
Sep 8, 2026 6w ago | 8-K | $11.31 $11.17 | ▼ −1.24% | ▼ −0.64% | $11.33 (+0.18%) |
Aug 20, 2026 9w ago | Insider Cluster | $11.03 $10.78 | ▼ −2.27% | ▼ −1.97% | $11.33 (+2.72%) |
Aug 3, 2026 12w ago | 8-K | $10.25 $10.00 | ▼ −2.49% | ▼ −2.29% | $11.33 (+10.54%) |
Aug 3, 2026 12w ago | Press Release | $10.25 $10.00 | ▼ −2.49% | ▼ −2.29% | $11.33 (+10.54%) |
Jul 30, 2026 12w ago | 8-K | $10.07 $10.11 | ▲ +0.40% | ▼ −1.03% | $11.33 (+12.51%) |
Jul 22, 2026 13w ago | 8-K | $10.14 $10.06 | ▼ −0.79% | ▼ −0.89% | $11.33 (+11.74%) |
Showing 10 of 21
US Market Status
Market Closed — Opens in 2h 29m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers